Compare FMC Corp (FMC) vs Manhattan Associates Inc (MANH) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

MANH trades at $156.66, down 1.22% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with 56% gross margins and 19.68% net income margins, though valuations appear elevated with a P/E of 43.85. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.24 surpassing the $1.10 estimate. However, ongoing legal investigations into fiduciary duties create investor uncertainty.

The outlook remains positive with analyst consensus at Buy (73%) and a $192.80 price target suggesting 23% upside. Key risks include high valuation multiples, legal investigations, and potential execution challenges in cloud transition. Earnings growth and AI initiatives provide catalysts, but investors should weigh premium valuation against legal overhang.